16 8 11 16 8 30 MRSA Key words: Kampo medicineinfluenza virusmrsaadjuvantmalaria I 2 591 1 1 3 6 3
2 1 1 1 II 1 7 Table 1. Component herbs of Hochuekki-toTJ-41 Herbs Astragali Radix Ginseng Radix Bupleuri Radix Auranti Nobilis Pericarpium Cimicifugae Rhizoma Atractylodis Lanceae Rhizoma Angelicae Radix Zizyphi Fructus Glycyrrhizae Radix Zingiberis Rhizoma per day Amount g 4.0 4.0 2.0 2.0 1.0 4.0 3.0 2.0 1.5 0.5 24.0 Fig. 1. Effect of Kampo medicines, Hochu-ekki-to TJ-41and Juzen-taiho-toTJ-48on production of antiinfluenza viral antibody in nasal cavity by secondary immunization of intranasally administrated influenza vaccine. 3,4 3 IFN IL-1α E2
Fig. 2. Effect of Sho-seiryu-to against infection of influenza virus APR834H1N1. IFN IL-1α 3 IL-1α IL-1α acetic acid cinnamylestercinnamic acid ethylester4-allylanisole7-hydroxycoumarin 5 6 2 1 10 Table 1 1 Fig. 3. Structure of 5,7,4-Trihydroxy-8- methoxyflavonef36. IgA 7 7 6 BALBc 7 0.1 gkg 2 2 IgA 6 IgA Fig. 1 2 IgG
Fig. 4. Effect of F36 on the survival of mice infected with mouse-adapted influenza virus APR834. IgA 2 Mori 8 3 MRSA MRSA 48 45 93.8225 MRSA 9 DPB 10 COPD COPD 11 COPD QOL Ito vancomycin minocycline MRSA 5 16 44 MRSA 12 Nishida 8 12 13 Helicobacter pylori H. pylori amoxicillin AMPC clarithromycincam CAM CAM CAM H. pylori CPY2052 AMPC 14 3 8 4 A H1N1
P P P P Fig. 5. Effect of Sho-seiryu-toTJ-19on production of antiviral antibody for secondary nasal inoculation of influenza HA vaccine in mice. Fig. 2 A H3N2 B IgA 15 HA IgA S S S Fig. 6. Structure of Pinellic acid. ELISPOT 16 HA T T IgA IgE 16
Fig. 7. Protection against influenza virus infection by intranasal administration of HA vaccine and onjisaponin F. Fig. 8. Structures of Artemisinin and related substances. 17
4 1 Scutellaria 134 F365,7,4-trihydroxy-8-methoxyflavoneFig. 3 18 F36 19 F36 0.5 mgkg 1 20 15 25 F36 1 0.5 mgkg 70 Fig. 4 20 F36 21 F36 22 5 IgG IgA 1 IgG 2 2 IgA Fig. 5 15 23 91213 8 9S 12S 13S -Trihydroxy-10E -octadecenoic acidfig. 6 24 1 µ g IgA 25 F 2 IgA Fig. 7 6 SARS Fig. 8 26 ATP SERCA SERCA 27 SARS 28 III 1 p. 69741997 2
20: 34, 2003 3 202: 414422, 2002 4 Nagai T, Yamada H: In vivo anti-influenza virus activity of KampoJapanese herbalmedicinesho-seiryu- Toand its mode of action. Int J Immunopharmacol 16: 605613, 1994 5 Kurokawa M, Kumeda C A, Yamamura J, et al: Antipyretic activity of cinnamyl derivatives and related compounds in influenza virus-infected mice. Eur J Pharmacol 348: 4551, 1995 6 Matsuda H, Moriura T, Kubo M : Pharmacological study on kanpo-hozai. III. Effect of Kakkon-to on immune responses. J Med Pharm Soc WAKAN-YAKU 7: 3545, 1990 7 19: 114, 2002 8 Mori K, Kido T, Daikuhara H, et al: Effect of Hochuekki-toTJ-41, a Japanese herbal medicine, on the survival of mice infected with influenza virus. Antiviral Res 44: 103111, 1999 9 MRSA 47: 373377, 2003 10 DPB 6: 125132, 1992 11 COPD 56: 105109, 1997 12 Ito T, Ito H, Kikuchi T: Five cases of MRSA-infected patients with cerebrovascular disorder and in a bedridden condition, for whom Bu-Zhong-Yi-Qi-Tang Hochu-ekki-towas useful. Am J Chinese Med 28: 401408, 2000 13 Nishida S: Effect of Hochu-ekki-to on asymptomatic MRSA bacteriuria. J Infect Chemother 9: 5861, 2003 14 Yan X, Kita M, Minami M, et al: Antibacterial effect of Kampo herbal formulation Hochu-ekki-toBu-Zhong- Yi-Qi-Tangon Helicobacter pylori infection in mice. Microbiol Immunol 46: 475482, 2002 15 Nagai T, Urata M, Yamada H: In vivo anti-influenza virus activity of KampoJapanese herbalmedicine Sho-seiryu-toEffects on aged mice, against subtypes of A viruses and B virus, and therapeutic effect. Immunopharmacol Immunotoxicol 18: 193208, 1996 16 Nagai T, Yamada H: In vivo anti-influenza virus activity of KampoJapanese herbalmedicinesho-seiryutostimulation of mucosal immune system and effect on allergic pulmonary inflammation model mice. Immunopharmacol Immunotoxicol 20: 267281, 1998 17 Nagai T, Hanawa T, Yamada H: In vivo anti-influenza virus activity of KampoJapanese herbalmedicine Ryo-kan-kyo-mi-shin-ge-nin-toon allergic pulmonary inflammation model mice. J Trad Med 15: 216224, 1998 18 Nagai T, Miyaichi Y, Tomimori T, et al: Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids. Chem Pharm Bull 38: 1329 1332, 1990 19 Nagai T, Miyaichi Y, Tomimori T, et al: Inhibition of mouse liver sialidase by plant flavonoides. Biochem Biophys Res Commun 163: 2531, 1989 20 Nagai T, Miyaichi Y, Tomimori T, et al: In vivo antiinfluenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Res 19: 207217, 1992 21 Nagai T, Moriguchi R, Suzuki Y, et al: Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7, 4-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis. Antiviral Res 26 : 11 25, 1995 22 von Itzstein M, Wu W Y, Kok G B, et al: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418423, 1993 23 Nagai T, Kiyohara H, Munakata K, et al: Pinellic acid from the tuber of Pinelliae ternata Breitenbach as an effective oral adjuvant for nasal influenza vaccine. Int Immunopharmacol 2: 11831193, 2002 24 Sunazuka T, Shirahata T, Yoshida K, et al: Total synthesis of pinellic acid, a potent oral adjuvant for nasal influenza vaccine. Determination of the relative and absolute configuration. Tetrahedron Lett 43: 1265 1268, 2002 25 Nagai T, Suzuki Y, Kiyohara H, et al: Onjisaponins, from the roots of Polygala tenuifolia WILLDENOW, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine 19 : 48244834, 2001 26 50: 355359, 2002 27 Eckstein-Ludwig U, Webb R J, Van Goethem I D A, et al: Artemisinins target the SERCA of Plasmodium falciparum. Nature 424: 957961, 2003 28 Cinatl J, Morgenstern B, Bauer G, et al: Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 : 20452046, 2003
Kampo medicine and chemotherapy Haruki Yamada Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University Oriental Medicine Research Center, The Kitasato Institute 591 Shirokane, Minato-ku, Tokyo, Japan Chinese traditional herbal medicine was introduced to Japan through the introduction of Buddhism from China in the 6th century and was established as KampoJapanese herbalmedicine during the Edo era after some modification, having a clinical history of more than 2000 years. Because Kampo medicine has often been used for the treatment of disease difficult to cure by orthodox medicine, it plays an important role in a medical treatment in Japan. Kampo medicine has been used as the decoction of the formula which were prescribed by several component herbs. Spray dried granule form was also developed for modern-day therapy. The action of orthodox medicine directs specifically to the nature and functions of a disease, whereas the action of Kampo medicine attempts to harmonize the disturbed pathophysiological condition of the patientsho,clinicallyas a whole to eventually equilibrate a normal physiological environment in the system. Although it has been believed that Kampo medicines is suitable for the treatment of chronic disease, several Kampo medicines have also been used for the treatment of infectious diseases such as typhoid fever which was described in the classical text book, Shanghanlun. Kampo medicine has been used separately depending on the progress of infectious disease and the decline of resistance of the body. Kampo medicine is effective for the treatment of several infectious diseases such as viral hepatitis, influenza viral infection, and MRSA and Helicobacter pyroli infections, proved by basic and clinical studies. Some Kampo medicines show direct action against infected microbes and defensive action through immunostimulation. Kampo medicine is expected to show preventive effects in elderly patients with decreased body action in transition to the serious stage of infectious disease. Medicinal herbs used in Kampo medicine also have a possibility to develop new antiinfectious agents such as the potent antimalarial drug Artemisinin.